Children's cough syrup recalled over bacteria concerns
(WKBN) – The presence of a bacterium that can cause two types of foodborne illnesses has prompted the recall of multiple lots of a children's cough syrup, a notice posted to the Food and Drug Administration's website announced this week.
Medtech Products Inc. is recalling five lots of Little Remedies Honey Cough Syrup due to the presence of Bacillus cereus, as well as the 'loss of shelf-stability,' the company explained.
The recalled products were distributed nationwide. They were sold 4-ounce bottles, both in stores and online, between Dec. 14, 2022, and June 4, 2025.
Identifying information, including the UPC and lot numbers, as well as the expiration dates, can be found below:
No other Little Remedies products were included in the recall.
While no serious adverse events have been reported in connection to the cough syrup, the FDA warns that Bacillus cereus can cause short-term illness and, in some cases, lead to death.
Bacillus cereus, or B. cereus, is a spore-forming bacterium that commonly exists in our environment, the Cleveland Clinic explains. Exposure to the toxin it creates can result in one of two types of illness — one described as a diarrheal syndrome and another as a vomiting syndrome. The first is characterized by cramps and watery diarrhea, while the second more commonly causes nausea and vomiting.
In severe cases, Bacillus cereus infection can lead to death.
Those who believe they may be suffering from an illness caused by Bacillus cereus are urged to contact a healthcare provider.
Customers who purchased the recalled Little Remedies cough syrup are being told to discard the product. Those with questions or refund requests can reach Medtech at 1-800-754-8853, by email at medicalaffairs@prestigebrands.com, or through the company's website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
19 hours ago
- New York Post
Children's cough syrup recalled due to possibly deadly food poisoning risk: ‘Stop using it immediately'
Parents: You might want to check your medicine cabinet. A New York-based pharmaceutical company is voluntarily recalling several batches of a popular children's cough syrup over fears they may be contaminated with harmful bacteria. The Food and Drug Administration is urging consumers to 'stop using it immediately' if they have any of the affected lots of Little Remedies® Honey Cough Syrup, according to an alert issued by the agency on Wednesday. Advertisement 3 The recalled product may contain Bacillus cereus Little Remedies The affected bottles were sold both in stores and online between Dec. 14, 2022, and June 4, 2025. The syrup comes in a 4-fluid-ounce amber bottle, packaged in an outer carton. Lot codes, which identify the recalled products, can be found on the bottle label and the bottom of the box. Advertisement The following five batches are affected: 3 FDA No other Little Remedies products are part of the recall. Syrup affected by the recall may be tainted with Bacillus cereus, a bacteria that can lead to two types of food-borne illnesses, according to the FDA. Advertisement One causes nausea, vomiting, and stomach cramps within six hours of exposure. The other triggers diarrhea and cramping, typically 8 to 16 hours after use. 3 The product is intended for children ages 1 year and older. redpepper82 – 'While healthy individuals may suffer only short-term illness, exposure to high levels of B. cereus can be fatal,' the agency said in an alert. So far, no illnesses have been reported. The FDA recommends that anyone experiencing symptoms seek medical attention and report any adverse reactions through their website. Advertisement Manufacturer, Medtech, is offering full refunds for the recalled products. Customers can contact the company directly by email at medicalaffairs@ through its website or by phone at (800) 754-8853 from 8:30 a.m. – 5:30 p.m. Monday through Friday.
Washington Post
20 hours ago
- Washington Post
How we plan to cut FDA drug approval time by months
Marty Makary is the commissioner of the Food and Drug Administration. For more than a century, the U.S. Food and Drug Administration has been a global leader in advancing medical cures, but in recent years, its regulatory framework has become an obstacle to innovation. Cumbersome requirements, poor communication and regulatory creep have made the United States less competitive in the global race for new drugs and treatments. Meanwhile, countries such as Australia and China, with more streamlined regulations, have become go-to destinations for clinical trials and early drug testing. The shift poses a risk not just to U.S. competitiveness but also to national security. To address it, the FDA must modernize. That's why I have just announced a pilot program that can slash the FDA's drug review time from 10 to 12 months to just one to two months. The program will make use of the idle time during clinical trials — time needed to see how the drug in question performs. Instead of submitting all the data at the end of a trial, qualifying manufacturers will be able to submit most elements of the application — including manufacturing details and drug labeling — while the trial is underway. The FDA will be able to review the early data and resolve any issues with the manufacturer at that time. Once the trial concludes, final data will be submitted. Then there will be about one month of FDA review, followed by a focused, one-day meeting with FDA scientists to reach a decision. This split-submission approach is entirely feasible — as shown by its success during Operation Warp Speed at the start of the covid-19 pandemic. This novel program tackles a common pain point voiced during my national listening tour: inaccessibility of FDA reviewers for clarifying questions. Pharmaceutical CEOs repeatedly told me a simple 15-minute call with their reviewer could save months of wasted work. Our new program adopts a real-time communication model, eliminating guesswork. No more mind-reading; drug developers will get straight answers when they're needed. As a surgical oncologist, I've experienced firsthand the benefits of team-based decision-making as a participant in 'tumor board' meetings where specialists collaborate to make critical decisions. A similar team approach can be applied at the FDA to evaluate the safety and efficacy of new drugs. In my first 12 weeks leading the FDA, we've made significant strides toward modernizing the agency. One example is the launch of Elsa, a tool powered by artificial intelligence that helps FDA reviewers sift through thousands of pages of data in minutes, instead of days. This tool is already being used by thousands of FDA staff daily, enabling them to focus more on what matters most: scientific expertise. Elsa doesn't replace human judgment but accelerates the review process, making the FDA more efficient and responsive. We're also speeding up approvals by phasing out outdated animal testing, replacing it with cutting-edge tools such as computational modeling and organ-on-a-chip toxicity testing, where a miniaturized, three-dimensional tissue mimics human function. These techniques are faster, cheaper and better at predicting human toxicity. Notably, about 90 percent of drugs that pass animal studies fail in humans. The FDA has even required animal studies on drugs already approved in Europe. We need both gold-standard science and common sense. Newer methods can be more predictive and humane. For drug developers, time is money. A previous valuable priority review program for rare pediatric diseases shortened FDA review time from 10 to 12 months to six. The market value of the six-month review was approximately $100 million to the pharmaceutical companies, showing that faster approval processes can be highly valuable. A one-month review process could be significantly more valuable and could incentivize companies to act on national priorities. These could include boosting domestic manufacturing for national security, addressing unmet public health needs or developing products for pandemic preparedness. The new national priority review program is designed to align speed, science and strategy. It rewards companies working on innovative solutions to real challenges faced by the American public, without sacrificing safety or the FDA's rigorous standards. By modernizing the FDA, we can ensure that the future of medicine is written in the United States. .
Yahoo
21 hours ago
- Yahoo
Popular Kids' Cough Medicine Recalled for Risk of Bacterial Infection That 'Can Cause Death'
Medtech Products is recalling five lots of its Little Remedies Honey Cough Syrup for bacterial contamination The food-borne illness causes gastrointestinal symptoms, which can be mild in healthy individuals but can cause death with long exposure The recall also extends to any lots within expiryA popular cough medicine for children is being recalled for possible bacterial contamination. Medtech Products issued a voluntary recall of five lots of its Little Remedies Honey Cough Syrup due to "the presence of Bacillus cereus and loss of shelf-stability," the United States Food and Drug Administration stated in an announcement on June 18. The product was distributed nationwide between Dec. 14, 2022, and June 4, 2025. Bacillus cereus is a bacteria that can cause two kinds of foodborne illnesses, both related to gastrointestinal issues. The first illness is marked by nausea, vomiting and stomach cramps that begin anywhere from one to six hours after consuming the contaminated product. The second illness, which tends to begin eight to 16 hours after consuming the contaminated product, is marked by stomach cramps and diarrhea. "Although healthy individuals may suffer only short term illness, exposure to high levels of foodborne B. cereus can cause death," the announcement read. The recall extends to Little Remedies Honey Cough Syrup in a 4 fl oz amber bottle with a UPC of 7-56184-10737-9. The lots included in the recall are as follows: Lot 0039, with an expiration date of 11/2025 Lot 0545, with an expiration date of 01/2026 Lot 0640, with an expiration date of 02/2026 Lot 0450, with an expiration date of 05/2026 Lot 1198, with an expiration date of 12/2026 Furthermore, all lots of the product that are still within expiry are included in the recall. Customers who bought the recalled product are urged to stop using it immediately and contact a doctor in the event of any symptoms that could be associated with using the product. The company will also offer reimbursement to those who purchased items from the recalled lots. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories. Medtech Products did not disclose how it discovered the bacterial contamination. Any further questions or concerns should be directed to Medtech at medicalaffairs@ on their site, or by phone at (800) 754-8853. Read the original article on People
